Literature DB >> 2600731

Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins.

M E Brewster, K S Estes, N Bodor.   

Abstract

The poor water solubility of alfaxalone (less than 5 micrograms/mL), a useful steroid anesthetic agent, was dramatically increased via complexation with a series of four cyclodextrins. The most effective agent was 2-hydroxypropyl-beta-cyclodextrin (2HPCD) which solubilized alfaxalone in a linear manner as a function of concentration. At a 2HPCD concentration of 50% w/v, approximately 80 mg/mL of alfaxalone was dissolved indicating an increase in aqueous solubility of over four orders of magnitude. The cyclodextrin solution was stable to autoclaving and could be conveniently lyophilized to yield a solid product.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2600731

Source DB:  PubMed          Journal:  J Parenter Sci Technol        ISSN: 0279-7976


  4 in total

1.  γ-aminobutyric acid type A α4, β2, and δ subunits assemble to produce more than one functionally distinct receptor type.

Authors:  Megan M Eaton; John Bracamontes; Hong-Jin Shu; Ping Li; Steven Mennerick; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2014-09-19       Impact factor: 4.436

2.  A cyclodextrin formulation to improve use of the anesthetic tribromoethanol (Avertin(®)).

Authors:  Arlene McDowell; Jessica A Fothergill; Azeem Khan; Natalie J Medlicott
Journal:  J Pharm Bioallied Sci       Date:  2014-01

3.  Effects of Alfaxalone or Propofol on Giant-Breed Dog Neonates Viability During Elective Caesarean Sections.

Authors:  Monica Melandri; Salvatore Alonge; Tanja Peric; Barbara Bolis; Maria C Veronesi
Journal:  Animals (Basel)       Date:  2019-11-13       Impact factor: 2.752

4.  Pharmacokinetics of intramuscular alfaxalone and its echocardiographic, cardiopulmonary and sedative effects in healthy dogs.

Authors:  Inga-Catalina Cruz-Benedetti; Isabelle Bublot; Thibault Ribas; Isabelle Fourel; Claus Vogl; Claire Dubois; Mathilde Milani; Keila Kazue Ida; Karine Portier
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.